Drug Database
BE

betamethasone (Bettamousse / Luxiq)

✓ Approved

Eisai Co., Ltd. · NR3C1 · 类固醇

什么是 betamethasone?

betamethasone 是一种类固醇,由Eisai Co., Ltd.研发。该药已获批,用于治疗相关适应症,给药途径:Topical。

药物档案

商品名Bettamousse, Luxiq
公司Eisai Co., Ltd.
药物类别类固醇, 小分子
分子靶点NR3C1
给药途径Topical
状态Approved

作用机制

分子靶点

betamethasone 作用于 1 个分子靶点:

NR3C1nuclear receptor subfamily 3 group C member 1 (GR, GCCR)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

betamethasone 针对 2 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Skin and subcutaneous tissue disordersPsoriasis✓ Approved
Skin and subcutaneous tissue disordersSeborrhoeic dermatitis✓ Approved

相关研究文献

PubMedPolymers2026-11-14

Biaxial Electrospinning of Poly(lactic acid)/Poly(butylene adipate-co-terephthalate) Blend and Polyvinylpyrrolidone Membranes for Topical Delivery of Betamethasone Valerate.

Schons Édina Liara ÉL, Salamanca Diogo José DJ, Fraga Gabriel Nardi GN, Dragunski Douglas Cardoso DC et al.

Psoriasis is one of the most common skin diseases in the world, and its treatment results in an improvement in the quality of life of patients, carried out mainly with the use of topical corticosteroids such as ointments and gels. As an alternative to conventional treatment of psoriasis, this work presents a study on the production and characterization of polymeric membranes containing betamethasone valerate produced by biaxial electrospinning. PVP has high solubility in water, resulting in rapid release of the incorporated drug. ECOVIO® (BASF, Ludwigshafen, Germany), composed of PLA and PBAT polymers, has good mechanical properties and forms membranes with controlled drug release, due to its hydrophobic characteristics. The produced membranes were characterized by SEM, FTIR, TGA, DSC and XRD. It was demonstrated that the selected polymers presented adequate conditions of electrospinning for membranes prepared in biaxial mode. Characterization showed a possible compatibility between the drug incorporated in the amorphous state and polymers, which also showed increased thermal stability. An increase in the availability of betamethasone valerate incorporated into the membranes (95%) in relation to the isolated active ingredient (20%) was observed in 24 h. Thus, according to the results obtained, the produced membrane is promising for the controlled release of betamethasone valerate.

PMID 43030012
阅读全文 →
PubMedCancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique2026-11-14

Combined excision and radiation therapy for keloid management: A systematic review.

Laiman Vincent V, Kurniawan Torana T, Ekaputra Ericko E, Meidania Lidya L et al.

Keloids are fibroproliferative disorders that pose therapeutic challenges due to their high recurrence rates, pain, and discomfort. However, the efficacy between different therapeutic modalities, particularly radiation therapy remains unclear. This systematic review aimed to compare the combination of excision and radiation therapy with other modalities. A systematic literature search from PubMed, Cochrane, and Web of Science was performed in December 2024. Search strategies with keywords related to "keloid", "radiation therapy", "treatment", and "outcome" were performed. Search was limited to prospective clinical trials that compared excision combined with radiation therapy to other keloid treatment modalities. A total of 723 studies were screened and six were included which reported 375 patients with a total of 427 lesions. Radiation therapy doses ranged from 0.8 Gy to 18 Gy, with fractions ranging from one to four. Postoperative irradiation was delivered on the same day or within 48 hours postoperatively. Excision combined with radiation therapy demonstrated higher complete response rates and better pain resolution compared to cryotherapy with triamcinolone acetonide, cryotherapy alone, and betamethasone with 5-fluorouracil, with or without excision. Hyperpigmentation was more commonly reported with excision and radiation therapy, while hypopigmentation was more frequent with other treatments. Studies with patient satisfaction data reported higher satisfaction after combination of excision and radiation therapy compared to other modalities. Excision combined with radiation therapy showed superior outcome compared to other modalities, particularly cryotherapy-based treatment, with higher pain resolution, and patient satisfaction. Notably, brachytherapy yielded the most favorable results in keloid treatment, with earlier postoperative irradiation suggestive of better control.

PMID 43025272
阅读全文 →
PubMedCureus2026-11-12

Iatrogenic Cushing Syndrome With Hypothalamic-Pituitary-Adrenal Axis Suppression in a Two-Month-Old Infant Following Unsupervised Topical Corticosteroid Use: A Case Report.

Bendouz Soukaina S, Lachraf Hind H, Bella Houda H, Imane Zineb Z et al.

Topical corticosteroids are commonly prescribed in pediatric dermatology; however, systemic adverse effects may occur rapidly in infants due to increased percutaneous absorption, the occlusive effect of diapers, and the immaturity of the hypothalamic-pituitary-adrenal (HPA) axis. We report the case of a two-month-old, 6 kg male infant who developed iatrogenic Cushing syndrome following approximately seven weeks of daily and repeated unsupervised application of a betamethasone valerate 0.1% topical corticosteroid to the diaper area for the treatment of diaper rash. Clinical examination revealed moon facies, a buffalo hump, and facio-truncal obesity. Laboratory evaluation showed suppressed morning cortisol at 5 µg/L (reference: 50-230 µg/L) and undetectable adrenocorticotropic hormone (ACTH) at 2.47 pg/mL (reference: 7-63 pg/mL), consistent with secondary adrenal insufficiency due to HPA axis suppression; brain CT showed no structural abnormality of clinical relevance. Management consisted of gradual withdrawal of the topical corticosteroid over four weeks, physiologic hydrocortisone replacement therapy at 8-10 mg/m²/day in three divided doses, and close clinical and biochemical follow-up. Biochemical recovery was suggested by normalization of morning cortisol to 272 µg/L, allowing progressive tapering and the discontinuation of hydrocortisone over six weeks without any episode of acute adrenal insufficiency. The family received structured education regarding the risks of unsupervised corticosteroid use and the warning signs of adrenal crisis. This case underscores that even moderate-to-potent topical corticosteroids applied to occluded skin areas can cause significant systemic toxicity in this vulnerable population and highlights the critical importance of parental education, appropriate prescribing guidance, and vigilant monitoring to prevent this avoidable complication.

PMID 43017263
阅读全文 →
PubMedObstetrics and gynecology2026-11-10

Hospital-Level Variation in Antenatal Corticosteroid Use for Late Preterm Births.

Clapp Mark A MA, Lee Dohyun D, Li Siguo S, James Kaitlyn E KE et al.

To determine whether and to what extent hospitals across the United States vary in their use of late preterm steroids. This was a retrospective cohort study of singleton births with known gestational ages identified in the Premier Healthcare Database from 2015 to 2022. The primary variable of interest was hospital-level adoption of antenatal corticosteroid use for late preterm singleton deliveries, calculated as the proportion of late preterm singleton births (34-36 completed weeks of gestation) with any betamethasone exposure during the same late preterm period. Hospital adoption was defined as the weighted average rate of steroid administration among late preterm births across the entire postperiod. Hospitals were ranked by their late preterm steroid adoption rates and categorized by quartile based on the empirical distribution. Temporal trends were assessed using annual hospital-level adoption rates and visualized using time series plots and distributional plots. A logistic regression model was constructed to identify hospital characteristics associated with being a highest-quartile adopter. The analysis cohort included 726 hospitals and 5,109,270 births, of which 309,837 (6.1%) were singleton late preterm births. Hospital steroid exposure rates ranged from 0% to 92% and were categorized into quartiles based on overall exposure rate, with cutoffs at 22.4%, 33.9%, and 45.1%. Median exposure rates increased progressively across quartiles, from 15.4% (IQR 10.0-18.9%) in the lowest-adopting hospitals (quartile 1) to 54.3% (IQR 49.1-61.0%) in the highest-adopting hospitals (quartile 4), with substantial within-quartile variation. In the multivariable model, urban location was a strong predictor of high adoption after adjustment (adjusted odds ratio [aOR] 2.03; 95% CI, 1.04-4.02, P=.04). Compared with Midwestern hospitals, Southern hospitals had significantly lower odds of being high adopters (aOR 0.32; 95% CI, 0.17-0.61, P<.001). Among clinical case mix variables, a higher proportion of late preterm births at 34 weeks of gestation was strongly associated with high adoption (aOR 2.39; 95% CI, 1.73-3.36, P<.001). After the publication of the ALPS (Antenatal Late Preterm Steroids) trial, the adoption of late preterm steroid use was heterogeneous among U.S. hospitals. These findings highlight the need for a more in-depth exploration of local factors that drive the adoption of evidence-based practices outside of observable hospital characteristics.

PMID 43008238
阅读全文 →
PubMedBMC anesthesiology2026-11-10

Erector spinae plane block in a patient with post-thoracotomy pain syndrome and intercostal neuralgia presenting with late-onset myoclonus: a case report.

Altunbag Yavuz Eda E, Seker Dincer Firat DF, Bayram Mustafa Gokhan MG, Yavuz Adil Ugur AU

Post-thoracotomy pain syndrome (PTPS) is a complex post-surgical chronic pain condition of the chest wall involving neuropathic, nociceptive, and nociplastic components, with intercostal neuralgia contributing in some cases. Intercostal neuralgia may occasionally present with motor manifestations, although such presentations have been infrequently described in the literature. Management of chronic PTPS remains challenging, particularly in cases refractory to medical therapy. The erector spinae plane block (ESPB) has been described as a regional analgesia technique in acute and chronic thoracic pain; however, its role in PTPS associated with motor symptoms has not been well defined. We report the case of a 60-year-old male who presented with severe chronic neuropathic pain in the left hemithorax seven years after undergoing a left posterolateral thoracotomy for lung mass excision. The pain was accompanied by late-onset myoclonus localized to the intercostal nerve distribution. Physical examination revealed hyperalgesia and high-frequency muscle spasms along the left T2-T6 dermatomes, with pain intensity rated as 8-9/10 on the Numeric Rating Scale (NRS; 0 = no pain, 10 = worst imaginable pain). Imaging studies showed expected postsurgical changes of the chest wall, without evidence of additional structural pathology contributing to the patient's symptoms. Differential diagnoses, including herpes zoster infection and thoracotomy-related long thoracic and thoracodorsal nerve injuries, were considered less likely based on the clinical findings. With a preliminary diagnosis of PTPS and intercostal neuralgia, ultrasound-guided ESPB was performed at the T4 level using bupivacaine, lidocaine, and dexamethasone. Significant reduction in pain scores (NRS 1-2/10) and muscle spasm frequency was observed within 15 min. Due to recurrence of symptoms after 24 h, a second ESPB using bupivacaine and betamethasone was performed, followed by near-complete resolution of pain (NRS 0-1/10) and disappearance of muscle spasms. No complications were observed. The patient was discharged with oral neuropathic pain medication and referred for outpatient pain management follow-up. Telephone follow-up demonstrated significant symptom improvement for approximately three weeks. This case describes the use of ultrasound-guided ESPB in a patient with PTPS and intercostal neuralgia accompanied by late-onset myoclonic symptoms. ESPB was followed by rapid improvement in pain and reduction in involuntary muscle spasms. These observations may support further discussion of the possible role of ESPB in selected patients with PTPS, intercostal neuralgia, and associated motor manifestations.

PMID 43004169
阅读全文 →
PubMedDrug delivery and translational research2026-11-04

Development and evaluation of a microneedle-assisted transdermal delivery system for compound betamethasone in atopic dermatitis.

Wang Si-Ning SN, Qiao Xiaojing X, Du Fangzhi F, Chen Jing J et al.

Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by skin barrier dysfunctio​n and immune dysregulation, which may influence topical drug penetration and therapeutic efficacy. This study evaluated a microneedle-assisted approach to enhance the cutaneous delivery of compound betamethasone in AD. Franz diffusion cell experiments demonstrated 3.29-fold and 4.67-fold increases in the 24-h cumulative permeation of betamethasone dipropionate (BDP) and betamethasone sodium phosphate (BSP), respectively, compared with passive application. In vivo fluorescence imaging showed greater penetration depth of fluorescein sodium following microneedle treatment, while histological examination revealed transient epidermal disruption. In a 2,4-dinitrochlorobenzene (DNCB)-induced AD mouse model, the combined treatment was associated with reduced epidermal thickening, mast cell accumulation, and serum IgE and IL-13 levels. In a pilot split-body clinical study involving 28 participants with mild-to-moderate AD, the microneedle + compound betamethasone-treated side showed greater improvements in Scoring Atopic Dermatitis (SCORAD) intensity and numeric rating scale (NRS) pruritus scores than the contralateral microneedle + saline control side after 7 days. No serious adverse events were observed during the study period. These findings demonstrate enhanced cutaneous permeation of compound betamethasone following microneedle-assisted application and provide preliminary evidence of therapeutic activity and short-term tolerability in AD.

PMID 42981018
阅读全文 →

注册免费账户还可查看另外 6199 篇文献

免费注册查看全部文献 →

了解更多betamethasone